Wu X, Huang Q, Chen X, Zhang B, Liang J, Zhang B
Theranostics. 2025; 15(2):605-631.
PMID: 39744696
PMC: 11671382.
DOI: 10.7150/thno.105423.
Cao Y, Yi Y, Han C, Shi B
Front Immunol. 2024; 15:1476030.
PMID: 39493763
PMC: 11530992.
DOI: 10.3389/fimmu.2024.1476030.
Hwang K, Yun J, Kim H
Int J Mol Sci. 2023; 24(21).
PMID: 37958805
PMC: 10650174.
DOI: 10.3390/ijms242115823.
Bao J, Betzler A, Hess J, Brunner C
Front Immunol. 2023; 14:1233085.
PMID: 37868967
PMC: 10586314.
DOI: 10.3389/fimmu.2023.1233085.
Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y
Cancer Cell. 2023; 41(8):1407-1426.e9.
PMID: 37419119
PMC: 10528152.
DOI: 10.1016/j.ccell.2023.06.005.
Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
Deng G, He J, Huang Q, Li T, Huang Z, Gao S
Cancers (Basel). 2023; 15(8).
PMID: 37190284
PMC: 10136622.
DOI: 10.3390/cancers15082356.
NF-κB signaling in inflammation and cancer.
Zhang T, Ma C, Zhang Z, Zhang H, Hu H
MedComm (2020). 2022; 2(4):618-653.
PMID: 34977871
PMC: 8706767.
DOI: 10.1002/mco2.104.
CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.
Gao S, Liu S, Wang G, Zhou G
Life (Basel). 2021; 11(12).
PMID: 34947813
PMC: 8708574.
DOI: 10.3390/life11121282.
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance.
Zhong S, Huang C, Chen Z, Chen Z, Luo J
J Clin Med. 2021; 10(21).
PMID: 34768524
PMC: 8584457.
DOI: 10.3390/jcm10215000.
Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L, Zhang Y, Zhao Y, Wei Q, Zhao Y, Yi Q
Front Cell Neurosci. 2021; 15:704344.
PMID: 34335194
PMC: 8322528.
DOI: 10.3389/fncel.2021.704344.
The tumor microenvironment and immune responses in prostate cancer patients.
Kwon J, Bryant R, Parkes E
Endocr Relat Cancer. 2021; 28(8):T95-T107.
PMID: 34128831
PMC: 8345898.
DOI: 10.1530/ERC-21-0149.
Regulation of gene transcription of B lymphoma Mo-MLV insertion region 1 homolog (Review).
Zhou M, Xu Q, Huang D, Luo L
Biomed Rep. 2021; 14(6):52.
PMID: 33884195
PMC: 8056379.
DOI: 10.3892/br.2021.1428.
Circular RNA circ-0016068 Promotes the Growth, Migration, and Invasion of Prostate Cancer Cells by Regulating the miR-330-3p/BMI-1 Axis as a Competing Endogenous RNA.
Li Q, Wang W, Zhang M, Sun W, Shi W, Li F
Front Cell Dev Biol. 2020; 8:827.
PMID: 32984325
PMC: 7479067.
DOI: 10.3389/fcell.2020.00827.
How Prostate Cancer Cells Use Strategy Instead of Brute Force to Achieve Metastasis.
Tharp D, Nandana S
Cancers (Basel). 2019; 11(12).
PMID: 31817000
PMC: 6966655.
DOI: 10.3390/cancers11121928.
The Role of Tumor-Infiltrating B Cells in Tumor Immunity.
Guo F, Cui J
J Oncol. 2019; 2019:2592419.
PMID: 31662750
PMC: 6778893.
DOI: 10.1155/2019/2592419.
Double-edge Role of B Cells in Tumor Immunity: Potential Molecular Mechanism.
Zhao K, Yang X, Jin H, Zhao L, Hu J, Qin W
Curr Med Sci. 2019; 39(5):685-689.
PMID: 31612383
DOI: 10.1007/s11596-019-2092-5.
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
Wang D, Yang L, Yu W, Wu Q, Lian J, Li F
J Immunother Cancer. 2019; 7(1):215.
PMID: 31395078
PMC: 6688336.
DOI: 10.1186/s40425-019-0701-2.
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.
Testa U, Castelli G, Pelosi E
Medicines (Basel). 2019; 6(3).
PMID: 31366128
PMC: 6789661.
DOI: 10.3390/medicines6030082.
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
Su W, Han H, Wang Y, Zhang B, Zhou B, Cheng Y
Cancer Cell. 2019; 36(2):139-155.e10.
PMID: 31327655
PMC: 7210785.
DOI: 10.1016/j.ccell.2019.06.009.
Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.
Paul A, Edwards J, Pepper C, Mackay S
Cells. 2018; 7(10).
PMID: 30347849
PMC: 6210445.
DOI: 10.3390/cells7100176.